Evidence map›Paper›PMID 26573825›Full record

ArticleBMC infectious diseases2015

Health system delay in treatment of multidrug resistant tuberculosis patients in Bangladesh.

Mahfuza Rifat, John Hall, Christopher Oldmeadow, Ashaque Husain, Abul Hasnat Milton

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Uncovering reasons for treatment initiation delays among children with TB in Lima, Peru.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2020
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2017
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Mahfuza RifatSchool of Medicine and Public Health, Faculty of Health and Medicine, the University of Newcastle, HMRI Building Lot 1 Kookaburra Circuit, New Lambton Heights, Newcastle, NSW, 2305, Australia. mahfuza.rifat@uon.edu.au.
John HallSchool of Medicine and Public Health, Faculty of Health and Medicine, the University of Newcastle, HMRI Building Lot 1 Kookaburra Circuit, New Lambton Heights, Newcastle, NSW, 2305, Australia. john.hall@newcastle.edu.au.
Christopher OldmeadowSchool of Medicine and Public Health, Faculty of Health and Medicine, the University of Newcastle, HMRI Building Lot 1 Kookaburra Circuit, New Lambton Heights, Newcastle, NSW, 2305, Australia. christopher.oldmeadow@newcastle.edu.au.
Ashaque HusainNational Tuberculosis Control Programme, Directorate General of Health Services, Dhaka, Bangladesh. ashek.dr@gmail.com.
Abul Hasnat MiltonSchool of Medicine and Public Health, Faculty of Health and Medicine, the University of Newcastle, HMRI Building Lot 1 Kookaburra Circuit, New Lambton Heights, Newcastle, NSW, 2305, Australia. milton.hasnat@newcastle.edu.au.
University of Newcastle Australia · AUDirectorate General of Health Services · BD

Funding

Wellcome Trust 100714
6 · The paper itself

Abstract

backgroundBangladesh is one of the 27 high burden countries for multidrug resistant tuberculosis listed by the World Health Organization. Delay in multidrug resistant tuberculosis treatment may allow progression of the disease and affect the attempts to curb transmission of drug resistant tuberculosis. The main objective of this study was to investigate the health system delay in multidrug resistant tuberculosis treatment in Bangladesh and to explore the factors related to the delay.

methodsInformation related to the delay was collected as part of a previously conducted case-control study. The current study restricts analysis to patients with multidrug resistant tuberculosis who were diagnosed using rapid diagnostic methods (Xpert MTB/RIF or the line probe assay). Information was collected by face-to-face interviews and through record reviews from all three Government hospitals providing multidrug resistant tuberculosis services, from September 2012 to April 2013. Multivariable regression analysis was performed using Bootstrap variance estimators. Definitions were as follows: Provider delay: time between visiting a provider for first consultation on MDR-TB related symptom to visiting a designated diagnostic centre for testing; Diagnostic delay: time from date of diagnostic sample provided to date of result; Treatment initiation delay: time between the date of diagnosis and date of treatment initiation; Health system delay: time between visiting a provider to start of treatment. Health system delay was derived by adding provider delay, diagnostic delay and treatment initiation delay.

resultsThe 207 multidrug resistant tuberculosis patients experienced a health system delay of median 7.1 weeks. The health system delay consists of provider delay (median 4 weeks), diagnostic delay (median 5 days) and treatment initiation delay (median 10 days). Health system delay (Coefficient: 37.7; 95 %; CI 15.0-60.4; p 0.003) was associated with the visit to private practitioners for first consultation.

conclusionsDiagnosis time for multidrug resistant tuberculosis was fast using the rapid tests. However, some degree of delay was present in treatment initiation, after diagnosis. The most effective way to reduce health system delay would be through strategies such as engaging private practitioners in multidrug resistant tuberculosis control.

Indexed as

AdultBangladeshCase-Control StudiesDelayed DiagnosisDelivery of Health CareFemaleHumansMaleReferral and ConsultationSocioeconomic FactorsTuberculosis, Multidrug-Resistant

Identifiers

PMID26573825
PMCPMC4647619
OpenAlexW2175813074

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.